| Gene symbol | CD40LG | Synonyms | CD154, CD40L, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD40 ligand | ||||
| Gene symbol | LAMP3 | Synonyms | CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3, TSC403 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q27.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | lysosomal associated membrane protein 3 | ||||
| Gene symbol | CD63 | Synonyms | AD1, HOP-26, ME491, MLA1, OMA81H, Pltgp40, TSPAN30 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12q13.2 | dbXrefs | |
| Description | CD63 molecule | ||||
| Gene symbol | TLR4 | Synonyms | ARMD10, CD284, TLR-4, TOLL | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | toll like receptor 4 | ||||
| GTO ID | GTC1344 |
| Trial ID | NCT01066390 |
| Disease | Melanoma |
| Altered gene | CD40LG|TLR4|LAMP3|ME491 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | TriMix-DC |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma |
| Year | 2009 |
| Country | Belgium |
| Company sponsor | Bart Neyns |
| Other ID(s) | 2009-015748-40 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||||||
|
|||||||||||
| Cohort2: dose level 2 | |||||||||||
|
|||||||||||
| Cohort3: dose level 3 | |||||||||||
|
|||||||||||
| Cohort4: dose level 4 | |||||||||||
|
|||||||||||